Immunotherapy has very different clinical applications in the fields of immuno-oncology, autoimmune diseases and transplantation. But in terms of immune response, the same immunological targets and immune cells may be involved during the mechanisms of stimulation and tolerance. The understanding of these targets and of their individual roles enable the identification of optimized stimulation or regulation therapies, according to the immune function to be restored in a selected pathology
In immuno-oncology, autoimmune diseases and transplantation, the medical need for new therapeutic appproaches remains significant. Through its development programs, OSE Immunotherapeutics addresses patients suffering from seemingly distinct diseases which, in fact, involve the same key cells playing major roles, namely effector and regulator cells. For these patients, the targeted therapeutic response is the restoration of their immune functions.
Metastatic cancers : There are currently a lack of therapeutic solutions for metastatic cancers. During the last two American Society of Clinical Oncology (ASCO) congresses in 2014 and 2015, the topic of immunotherapy was presented as a real hope of stabilization and even remission for some patients. “Strategies using the immune system against the tumor are considered a huge scientific breakthrough,” noted the prestigious journal, Science (December 2013). “It’s not about targeting the tumor only, anymore, but to arm the immune system”.
Autoimmune diseases : Their occurrence makes this group a major health issue, just as cardiovascular or cancer diseases. Autoimmune diseases are chronic, often they affect young patients and require long term treatments.
Transplantations and marrow transplants : In recent years, a variety of new immunosuppressant medications have been approved, widening the scope of existing therapeutic options. Nevertheless, all current protocols require the patient to take immunosuppression medication on a daily basis and for the rest of his life, in order to minimize the risk of chronic rejection, which can take months or years to manifest, clinically. For example, in 15 years, the six-year survival rate of renal transplant has increased from 66% to 80%. However, the rate of graft failure due to a chronic rejection and to nephrotoxicity of immunosuppressors (5% per year) has not improved over the same time period. Therefore, the need for new and innovative approaches still exists.